Slate Medicines

Private

#Migraine #Headache Disorders #PACAP Pathway #Neuroscience #Chronic Pain

Slate Medicines is a clinical-stage biotechnology company developing anti-PACAP therapeutics for migraine and headache disorders. The company launched in 2026 with a $130M Series A to advance its lead program SLTE-1009 and other PACAP-pathway candidates, joining a competitive class of next-generation migraine developers seeking to challenge the CGRP inhibitor standard of care.

Company Info

Sector: Biotechnology / Neuroscience / Pain

Headquarters: Raleigh, North Carolina, USA

Founded: 2025

Website: www.slatemedicines.com/

Funding Round: Series A (February 2026)

Total Funding: $130M

Funding & Investor Relations

Notable Investors

RA Capital Management
Forbion
Foresite Capital

IPO Outlook / Plans

None publicly disclosed; private clinical-stage company focused on advancing lead program toward clinical trials.

Upcoming Milestones & Key Dates

Late 2026 / 2027

Regulatory

IND filing and Phase 1 initiation for SLTE-1009

Clinical Development Pipeline

SLTE-1009

Target: Anti-PACAP monoclonal antibody

Migraine prevention (chronic and episodic)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

SLTE-2000 series

Target: PACAP receptor antagonists and related pathway

Headache disorders and chronic pain

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Gregory Oakes

Chief Executive Officer

Neil Buckley

President and Chief Operating Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →